Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 1 Lupus Erythematosus, Systemic 1 Infections 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 9 Ciprofloxacin 8 Voriconazole 5 Vancomycin 4 Caspofungin 4 Amoxicillin-Potassium Clavulanate Combination 4 gamma-Globulins 3 Fluconazole 3 Filgrastim 3 Daptomycin 3 Antibiotic Prophylaxis 3 plerixafor 2 liposomal amphotericin B 2 Whole-Body Irradiation 2 Trimethoprim 2 Therapeutics 2 Sulfamethoxazole 2 Saline Solution 2 Rituximab 2 Ribavirin 2 Polymerase Chain Reaction 2 Piperacillin, Tazobactam Drug Combination 2 Peripheral Blood Stem Cell Transplantation 2 Pentetic Acid 2 Moxifloxacin 2 Melphalan 2 Levofloxacin 2 Lenalidomide 2 Itraconazole 2 Immunoglobulins, Intravenous 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Infections × anifrolumab × Clear all

NCT07000110 2026-05-20

SIMA

AstraZeneca

Infections, Lupus Erythematosus, Systemic, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡